Treatment of skin lesions and pruritus in prurigo nodularis patients
AssigneeGalderma Holding SA
InventorChristophe PIKETTY
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
Claims27
-29. (canceled)
A method of treating skin lesions and pruritus in a subject having chronic prurigo (CP), comprising administering about 30 mg to about 60 mg of nemolizumab or an equivalent thereof to the subject.
A method of treating prurigo nodularis (PN), comprising subcutaneously administering about 30 mg to about 60 mg of nemolizumab to a subject with PN.
Dependencies are inferred from the claim text.